Published in Eur Urol on August 01, 2002
Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Prostate Cancer Prostatic Dis (2011) 0.86
New techniques and management options for localized prostate cancer. Rev Urol (2006) 0.78
The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer. World J Surg Oncol (2015) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21
Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2012) 4.07
Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst (2007) 3.26
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol (2008) 2.92
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol (2012) 2.79
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ (2014) 2.61
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst (2010) 2.45
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27
Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol (2008) 2.17
Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05
Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol (2012) 1.96
Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol (2006) 1.94
No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int (2010) 1.94
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol (2007) 1.93
Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer (2002) 1.89
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol (2010) 1.75
Incidence of prostate cancer after termination of screening in a population-based randomised screening trial. Eur Urol (2013) 1.64
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A (2010) 1.59
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol (2003) 1.49
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int (2013) 1.39
Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study. Eur J Cancer (2007) 1.35
Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Cancer (2009) 1.32
Towards an optimal interval for prostate cancer screening. Eur Urol (2011) 1.27
Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry. Scand J Urol Nephrol (2003) 1.20
The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Göteborg randomised population-based prostate cancer screening trial. Eur J Cancer (2010) 1.20
The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol (2005) 1.20
Post-radical prostatectomy inguinal hernia: a simple surgical intervention can substantially reduce the incidence--results from a prospective randomized trial. J Urol (2010) 1.19
Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer (2010) 1.13
Lead-time in the European Randomised Study of Screening for Prostate Cancer. Eur J Cancer (2010) 1.13
Does initial surveillance in early prostate cancer reduce the chance of cure by radical prostatectomy?--A case control study. Scand J Urol Nephrol (2003) 1.07
Four-hundredfold overestimation of biopsy mortality. BJU Int (2013) 1.07
High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol (2011) 1.06
The impact of birth weight on prostate cancer incidence and mortality in a population-based study of men born in 1913 and followed up from 50 to 85 years of age. Prostate (2007) 1.02
False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer (2011) 1.02
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant (2008) 1.00
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2012) 0.94
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men. BJU Int (2009) 0.94
Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy. Scand J Urol Nephrol (2009) 0.93
Inguinal hernia in stage M0 prostate cancer: a comparison of incidence in men treated with and without radical retropubic prostatectomy--an analysis of 1105 patients. Urology (2005) 0.93
LAPPRO: a prospective multicentre comparative study of robot-assisted laparoscopic and retropubic radical prostatectomy for prostate cancer. Scand J Urol Nephrol (2010) 0.92
Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. J Med Screen (2013) 0.92
Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scand J Urol Nephrol (2009) 0.91
Efficacy versus effectiveness study design within the European screening trial for prostate cancer: consequences for cancer incidence, overall mortality and cancer-specific mortality. J Med Screen (2012) 0.89
Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer. Int J Cancer (2006) 0.89
Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer. Eur Urol (2012) 0.87
Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. J Urol (2010) 0.87
Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands. Cancer Epidemiol Biomarkers Prev (2009) 0.87
Prediction of prostate cancer in unscreened men: external validation of a risk calculator. Eur J Cancer (2010) 0.87
Excess all-cause mortality in the evaluation of a screening trial to account for selective participation. J Med Screen (2013) 0.86
Prostate biopsy and anaesthesia: an overview. Scand J Urol Nephrol (2005) 0.86
Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer (2004) 0.85
Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening. Eur Urol (2003) 0.85
Patient and tumour-related factors for prediction of urinary incontinence after radical prostatectomy. Scand J Urol (2012) 0.83
Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3). Scand J Urol Nephrol (2003) 0.81
Single-dose orally administered quinolone appears to be sufficient antibiotic prophylaxis for radical retropubic prostatectomy. Scand J Urol Nephrol (2004) 0.81
Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate (2005) 0.80
Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. Urology (2003) 0.80
Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. J Urol (2003) 0.79
Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int (2012) 0.78
Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. Eur Urol (2004) 0.78
Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy? Acta Oncol (2005) 0.77
Effects of surgeon variability on oncologic and functional outcomes in a population-based setting. BMC Urol (2014) 0.75
Screening for prostate cancer. Ann Intern Med (2012) 0.75
Interobserver variability in the pathological assessment of radical prostatectomy specimens: findings of the Laparoscopic Prostatectomy Robot Open (LAPPRO) study. Scand J Urol (2013) 0.75
[In Process Citation]. Lakartidningen (2015) 0.75
Radical prostatectomy--long-term oncological outcome from a community hospital. Scand J Urol Nephrol (2003) 0.75
Geographical variation in incidence of prostate cancer in Sweden. Scand J Urol Nephrol (2005) 0.75